(PPBT) Purple Biotech Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PPBT) Purple Biotech Ltd. Complete Analysis Pack
Download Your Competitive Advantage
This Purple Biotech Ltd. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
No approved product
Purple Biotech Ltd. has no approved commercial product as of end-2025, so it generated no marketed-drug revenue and does not fit the Star box. Its 2025 portfolio remained clinical-stage, with value still tied to trials rather than scale sales. In BCG terms, this is a development pipeline, not a high-share growth engine.
0 revenue brands
Purple Biotech has no approved brand revenue, so this is not a true Star in the BCG sense. The company does not disclose product sales, and its commercial revenue is effectively $0, with value still driven by clinical readouts, not market share. That makes its pipeline, not a revenue brand, the main driver of upside.
CM24 Phase 1b/2
CM24 Phase 1b/2 is still a mid-stage asset, so it is not a market leader or a true Star in Purple Biotech Ltd.'s BCG Matrix. The program is being tested with anti-PD-1 therapy in non-small cell lung cancer and pancreatic cancer, which is promising science, but it remains early and unproven at this stage.
NT219 Phase 1/2
NT219 sits in Purple Biotech Ltd.'s Stars bucket only as a development bet, not a sales driver. It is still in Phase 1/2, has no approved indication, and is being tested in recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck.
That makes it a pipeline candidate with binary clinical risk, not a commercial leader. With no revenue, margin, or market-share base yet, its value rests on trial progress and data readouts, not current cash generation.
- Phase 1/2 asset
- No approved indication
- Tests two cancer settings
- Pipeline, not commercial
No mature franchise
Purple Biotech Ltd. has 0 approved oncology products and no recurring product sales, so it does not have a mature franchise. A Star needs high share in a growing market, but Purple Biotech is still tied to clinical readouts and partner deals, not market leadership. That makes future trial success the main value driver, not an established business.
- No mature oncology franchise
- 0 approved products
- Depends on trial success
- Partnering value still key
Purple Biotech: No Stars, Just Binary Trial Risk
Stars is not a fit for Purple Biotech Ltd. in 2025: it had 0 approved oncology products, no recurring product sales, and its value still depended on Phase 1/2 data, not market share. CM24 and NT219 are clinical bets, but neither is a commercial leader. So the upside is still binary trial risk, not a proven Star business.
| Asset | 2025 status | Star fit |
|---|---|---|
| CM24 | Phase 1b/2 | No |
| NT219 | Phase 1/2 | No |
| Purple Biotech Ltd. | 0 approved products | No |
What is included in the product
Detailed Word Document
BCG Matrix review of Purple Biotech Ltd.’s pipeline, pinpointing Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
One-page BCG Matrix for Purple Biotech Ltd. that pinpoints each unit’s role and priority fast
Reference Sources
Purple Biotech Ltd. Reference Sources provide a credible, traceable basis for key claims, helping decision-makers verify assumptions fast and trust the analysis.
Cash Cows
No marketed drug
Cash cows are mature products with high share and steady sales, but Purple Biotech Ltd. had no marketed drug as of end-2025. That means it had no product revenue stream that could reliably generate excess cash. So, in BCG terms, this bucket is empty for Purple Biotech Ltd., and funding still depends on financing and future clinical success.
0 product revenue
Purple Biotech Ltd. has 0 product revenue, so it has no Cash Cow to generate steady operating cash flow. As a development-stage biotech, it is still spending on R&D rather than harvesting profits, so cash burn stays the key issue. That means the Company still depends on external financing, not internal cash, to fund trials and operations.
No U.S. share
Purple Biotech Ltd. has no U.S.-approved oncology product, so it has no established share in any commercial U.S. cancer market. With no product sales, its 2025/2026 cash flows from the U.S. remain zero, so the "cash cow" profile does not apply. The company is still in development mode, not harvest mode.
R and D cash burn
Purple Biotech’s Phase 1b/2 and Phase 1/2 programs sit squarely in R&D cash burn: every site, patient visit, lab test, CRO fee, and regulatory filing adds cost before any revenue arrives. That makes this a pure cash consumer, not a mature cash cow.
The spend is ongoing and hard to cut quickly, so burn rises with trial length and enrollment pace. In BCG terms, this bucket drains cash that must be funded by existing reserves or new capital.
- Trial ops and monitoring drive recurring spend
- No product sales, so no offsetting cash flow
No dividend capacity
Purple Biotech Ltd has no dividend capacity because it has no recurring product profits to fund payouts, overhead, or new investment. In the latest reported period, its business remained development-stage, so any cash for operations came from financing, not from operating cash flow. That makes it a BCG "cash cow" only in name, not in cash generation.
- No recurring product profit
- Cash comes from financing
- No dividend support from operations
Purple Biotech: No Cash Cow, Just Cash Burn
Purple Biotech Ltd. had no Cash Cow in 2025/2026: product revenue was 0, and it had no marketed drug to harvest steady cash. Its late-stage pipeline still consumed cash through R&D, trials, and regulatory work, so the bucket stayed empty. In BCG terms, it remained a cash user, not a cash generator.
| Metric | 2025/2026 |
|---|---|
| Product revenue | 0 |
| Marketed drug | No |
| Cash cow status | None |
Preview Before You Purchase
Purple Biotech Ltd. Reference Sources
The Purple Biotech Ltd. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No mockups, no placeholder content—just the full, ready-to-use report. Once purchased, it’s instantly available for download, printing, or sharing with your team.
Dogs
No legacy commercial brand
Purple Biotech Ltd. has 0 legacy commercial brands, so there is no low-growth, low-share product to place in the Dogs box. The company, formerly Kitov Pharma, is focused on active development assets, not a sales franchise. In 2025-2026, its profile remains R&D-led, so this category is effectively empty.
No mature declining asset
Dogs do not fit Purple Biotech Ltd. well. Its main programs, including CM24 and NT219, are still in early clinical development, so they are not mature, declining assets in stagnant markets. The classic Dog profile is weak here, not a fair read.
No divestiture target disclosed
Dog assets are often sold or shut down, but Purple Biotech has not disclosed a declining commercial product to divest. Its portfolio is centered on 2 lead clinical programs, CM24 and NT219, so capital is still being directed to development rather than harvesting a weak asset. That makes the Dog bucket effectively empty for now.
No low-share commercial asset
Purple Biotech Ltd. has no approved products, so it has no low-share commercial asset to classify as a Dog. With no sales base, there is no weak brand in a slow market to cull or harvest.
The issue is pipeline risk, not product decay. In FY2024, Purple Biotech reported no product revenue and a net loss of $22.6 million, while cash and cash equivalents were $2.1 million at year-end.
No approved products
No commercial Dog asset
Risk sits in clinical failure
Pipeline risk only
Purple Biotech Ltd. is closer to a Question Mark than a pure Dog: its value sits in pipeline shots, while the main downside is clinical failure and the need to fund trials. If a program misses its endpoint, the spend turns into sunk R&D cost, not a Dog asset with steady cash flow. That means the real risk is not weak products today, but whether the pipeline can clear data and financing hurdles.
- Clinical risk can erase program value.
- Financing risk can force dilution.
- Failures become sunk R&D cost.
Dogs Missing: Purple Biotech Has No Revenue, Just Losses and Thin Cash
Dogs is effectively empty for Purple Biotech Ltd. The Company has no approved products or legacy sales brands, so there is no low-growth, low-share asset to harvest or divest. FY2024 showed no product revenue, a net loss of $22.6 million, and $2.1 million cash at year-end.
| Metric | FY2024 |
|---|---|
| Product revenue | 0 |
| Net loss | $22.6 million |
| Cash | $2.1 million |
Question Marks
CM24 Phase 1b/2
CM24 is Purple Biotech Ltd.’s monoclonal antibody against CEACAM1, now in Phase 1b/2 with anti-PD-1 checkpoint inhibitors in non-small cell lung cancer and pancreatic cancer.
It has zero revenue and zero market share, so its value still depends on clinical readouts, not sales.
That mid-stage profile fits a Question Mark: high upside if efficacy and safety hold, but still high cash burn and clinical risk.
NT219 Phase 1/2
NT219 is Purple Biotech Ltd.’s Phase 1/2 asset targeting IRS1, IRS2, and STAT signaling, aimed at recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. With early-stage clinical data only, its market share is still zero, so it sits in the Question Marks bucket. The upside is real if efficacy data improve, but 2025-2026 revenue impact remains limited until later-stage proof appears.
2 lead oncology assets
Purple Biotech’s pipeline is concentrated in 2 lead oncology assets, so the BCG "Question Marks" label fits: both are pre-commercial and value depends on trial readouts. That makes the story highly binary; one positive data set can re-rate the stock, while one miss can cut value fast. In this setup, cash burn and trial timing matter as much as science.
Combination therapy strategy
CM24 is still a Question Mark because Purple Biotech Ltd. is betting on combination use with anti-PD-1 agents, where the market can grow fast if response rates improve. Anti-PD-1 therapy is already a large base, with Merck’s Keytruda posting $29.5 billion in 2024 sales, so even a small efficacy gain could matter. But until Purple Biotech Ltd. shows strong clinical data, the value of this strategy remains uncertain.
- Combo use can widen the target market.
- Anti-PD-1 is a proven commercial anchor.
- Clinical proof is still the key risk.
Clinical-stage only
Purple Biotech Ltd. is a pure Clinical-stage only Question Mark: as of end-2025 it had no approved products and no product revenue, so value depends on whether its pipeline can win adoption. That makes the payoff binary: clinical success can turn a program into a Star, while failure can erase most of the asset value.
- No approved products at end-2025
- No product revenue at end-2025
- Pipeline value is still unproven
- Clinical win could re-rate sharply
Purple Biotech’s two Question Marks hinge on clinical readouts
Purple Biotech Ltd.’s Question Marks are CM24 and NT219: both are pre-commercial, early-stage oncology assets with zero revenue and no market share at end-2025. Their value still hinges on Phase 1/2 data, especially combo efficacy and safety. If readouts improve, upside can be sharp; if not, cash burn stays high.
| Asset | Stage | 2025 Status | BCG fit |
|---|---|---|---|
| CM24 | Phase 1b/2 | No revenue | Question Mark |
| NT219 | Phase 1/2 | No revenue | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.